{"brief_title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis", "brief_summary": "OBJECTIVES: I. Compare tolerance to and therapeutic impact of copolymer 1, a mixture of synthetic polypeptides, with placebo in patients with relapsing-remitting multiple sclerosis.", "detailed_description": "PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by participating institution. One group receives copolymer 1, a mixture of synthetic polypeptides composed of 4 amino acids, subcutaneously each day for 2 years. The other group receives an injection of placebo daily for 2 years.", "condition": ["Multiple Sclerosis"], "intervention_type": ["Drug"], "intervention_name": ["copolymer 1"], "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Clinically or laboratory-supported definite multiple sclerosis - Neurologically stable for at least 30 days prior to entry Expanded Disability Status Scale score no greater than 5 - At least 2 documented relapses within 2 years prior to entry Onset of first relapse at least 1 year prior to randomization --Prior/Concurrent Therapy-- - Biologic therapy: No prior copolymer 1 - Immunosuppressive therapy: No prior cytotoxic immunosuppressives, i.e.: Azathioprine Cyclophosphamide Cyclosporine At least 30 days since corticosteroids - Radiotherapy: No prior lymphoid irradiation --Patient Characteristics-- - Not HIV or HTLV-I seropositive No insulin-dependent diabetes mellitus No Lyme disease No requirement for aspirin or chronic nonsteroidal anti-inflammatory drugs No pregnant or nursing women Adequate contraception required of fertile women", "gender": "All", "minimum_age": "18 Years", "maximum_age": "45 Years", "healthy_volunteers": "No", "keyword": "rare disease", "mesh_term": ["Sclerosis", "Multiple Sclerosis", "Multiple Sclerosis, Relapsing-Remitting", "Glatiramer Acetate"], "id": "NCT00004814"}